Iridex Corporation will announce Q4 2024 financial results and provide a business update on March 27, 2025.
Quiver AI Summary
Iridex Corporation, a leader in laser-based medical systems for treating glaucoma and retinal diseases, announced that it will release its financial results for the fourth quarter and full year of 2024 on March 27, 2025, after market close. Following the announcement, management will host a conference call at 2:00 p.m. PT (5:00 p.m. ET), which investors can access by calling +1-888-596-4144 with the conference ID: 5685253. The call will also be available via a live and recorded webcast on Iridex's website. Iridex specializes in developing innovative ophthalmology solutions, including its proprietary MicroPulse® technology, and sells its products in over 100 countries.
Potential Positives
- Iridex Corporation plans to announce its financial results for Q4 and full year 2024, indicating transparency and a willingness to engage with investors.
- The upcoming conference call provides an opportunity for direct communication between the company's management and investors, fostering investor relations.
- Iridex's position as a leader in laser-based medical systems enhances its credibility and attractiveness to potential investors and partners.
Potential Negatives
- Failure to provide specific financial expectations or forecasts for the upcoming earnings release could indicate a lack of confidence in future performance.
- Scheduling the earnings call for later in the month may suggest that it’s a strategic delay, potentially raising concerns among investors about the financial stability or operational issues within the company.
- Absence of additional strategic initiatives or product updates in the press release might indicate stagnation or lack of innovation, which could affect investor sentiment.
FAQ
When will Iridex Corporation release its financial results?
Iridex plans to release its financial results for Q4 and full year 2024 on March 27, 2025.
What time is the Iridex conference call scheduled?
The conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET on March 27, 2025.
How can investors participate in the Iridex conference call?
Investors can join the call by dialing +1-888-596-4144 and using the conference ID: 5685253.
Where can I find the webcast of the Iridex conference call?
The live and recorded webcast will be available on the "Event Calendar" page on the Iridex website.
What products does Iridex Corporation focus on?
Iridex specializes in laser-based medical systems for glaucoma, diabetic macular edema, and other retinal diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRIX Hedge Fund Activity
We have seen 5 institutional investors add shares of $IRIX stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LONG FOCUS CAPITAL MANAGEMENT, LLC removed 61,827 shares (-61.8%) from their portfolio in Q4 2024, for an estimated $103,869
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 34,524 shares (-52.8%) from their portfolio in Q4 2024, for an estimated $58,000
- CITADEL ADVISORS LLC added 17,377 shares (+34.6%) to their portfolio in Q4 2024, for an estimated $29,193
- RENAISSANCE TECHNOLOGIES LLC removed 16,200 shares (-4.1%) from their portfolio in Q4 2024, for an estimated $27,216
- TRUIST FINANCIAL CORP added 12,979 shares (+inf%) to their portfolio in Q4 2024, for an estimated $21,804
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 6,975 shares (-9.1%) from their portfolio in Q4 2024, for an estimated $11,718
- UBS GROUP AG removed 3,586 shares (-22.6%) from their portfolio in Q4 2024, for an estimated $6,024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse ® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse ® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
[email protected]
